Ninety outpatients with histologically confirmed malignancy receiving chemotherapy entered a randomized cross-over trial to assess the antiemetic efficacy of low-dose metoclopramide versus methylprednisolone. Treatment consisted of either metoclopramide (MCP) 60 mg or methylprednisolone (MPN) 375 mg administered in 3 equal doses just prior to chemotherapy and 6 and 12 hours after treatment. Patients receiving MPN had significantly less nausea (p <0.001) and fewer episodes of vomiting (pp <0.0003) than patients receiving MCP. MPN also proved to be the more effective agent in cross-over trials. Both MPN and MCP were well tolerated. No important side effects were observed. MPN is a safe, effective, antiemetic treatment suitable for use in the outpatient.
|Number of pages||4|
|Publication status||Published - 1984|
ASJC Scopus subject areas
- Pharmacology (medical)
- Microbiology (medical)